Clinical Trials Browser

Carcinoma, Medullary × lutetium Lu 177 dotatate × Clear all

NCT06121271 2023-12-07

Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

Phase 2 Not yet recruiting

Carcinoma, Medullary

NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Phase 2 Withdrawn

CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary